JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $58 to $62.

June 05, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Intra-Cellular Therapies and raises the price target from $58 to $62.
The news of JP Morgan maintaining an Overweight rating and raising the price target for Intra-Cellular Therapies is positive for the stock. This indicates that the analyst believes the stock will outperform the market, and the increased price target suggests a higher potential upside. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100